These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 18922583)

  • 21. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.
    Sáiz PA; García-Portilla MP; Arango C; Morales B; Arias B; Corcoran P; Fernández JM; Alvarez V; Coto E; Bascarán MT; Bousoño M; Fañanas L; Bobes J
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):26-31. PubMed ID: 19766158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COMT polymorphisms as predictors of cognitive dysfunction during manic and mixed episodes in bipolar I disorder.
    Soeiro-de-Souza MG; Machado-Vieira R; Soares Bio D; Do Prado CM; Moreno RA
    Bipolar Disord; 2012 Aug; 14(5):554-64. PubMed ID: 22713126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
    Gunes A; Scordo MG; Jaanson P; Dahl ML
    Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No associations exist between five functional polymorphisms in the catechol-O-methyltransferase gene and schizophrenia in a Japanese population.
    Nunokawa A; Watanabe Y; Muratake T; Kaneko N; Koizumi M; Someya T
    Neurosci Res; 2007 Jul; 58(3):291-6. PubMed ID: 17482701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
    Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Ishida M; Furukori H; Kaneko S; Inoue Y; Otani K
    Pharmacogenetics; 2001 Aug; 11(6):545-50. PubMed ID: 11505224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
    Tybura P; Trześniowska-Drukała B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
    Psychiatry Res; 2014 Oct; 219(2):261-7. PubMed ID: 24930580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms.
    Gupta M; Chauhan C; Bhatnagar P; Gupta S; Grover S; Singh PK; Purushottam M; Mukherjee O; Jain S; Brahmachari SK; Kukreti R
    Pharmacogenomics; 2009 Feb; 10(2):277-91. PubMed ID: 19207030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families.
    Chen X; Wang X; O'Neill AF; Walsh D; Kendler KS
    Mol Psychiatry; 2004 Oct; 9(10):962-7. PubMed ID: 15124004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.
    Abdolmaleky HM; Cheng KH; Faraone SV; Wilcox M; Glatt SJ; Gao F; Smith CL; Shafa R; Aeali B; Carnevale J; Pan H; Papageorgis P; Ponte JF; Sivaraman V; Tsuang MT; Thiagalingam S
    Hum Mol Genet; 2006 Nov; 15(21):3132-45. PubMed ID: 16984965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance.
    Burdick KE; Funke B; Goldberg JF; Bates JA; Jaeger J; Kucherlapati R; Malhotra AK
    Bipolar Disord; 2007 Jun; 9(4):370-6. PubMed ID: 17547583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetics of Lesch's typology of alcoholism.
    Samochowiec J; Kucharska-Mazur J; Grzywacz A; Pelka-Wysiecka J; Mak M; Samochowiec A; Bienkowski P
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):423-7. PubMed ID: 17928119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. -141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population.
    Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Goti J; Sanchez V; Catalan R; Carne X
    Psychiatr Genet; 2008 Jun; 18(3):122-7. PubMed ID: 18496209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications.
    Weickert TW; Goldberg TE; Mishara A; Apud JA; Kolachana BS; Egan MF; Weinberger DR
    Biol Psychiatry; 2004 Nov; 56(9):677-82. PubMed ID: 15522252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
    Kibitov AA; Kiryanova EM; Salnikova LI; Bure IV; Shmukler AB; Kibitov AO
    Drug Metab Pers Ther; 2023 Jun; 38(2):133-142. PubMed ID: 36437548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.
    Gupta M; Bhatnagar P; Grover S; Kaur H; Baghel R; Bhasin Y; Chauhan C; Verma B; Manduva V; Mukherjee O; Purushottam M; Sharma A; Jain S; Brahmachari SK; Kukreti R
    Pharmacogenomics; 2009 Mar; 10(3):385-97. PubMed ID: 19290789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catechol-O-methyl transferase and schizophrenia.
    Sagud M; Mück-Seler D; Mihaljević-Peles A; Vuksan-Cusa B; Zivković M; Jakovljević M; Pivac N
    Psychiatr Danub; 2010 Jun; 22(2):270-4. PubMed ID: 20562760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study.
    Mihara K; Kondo T; Suzuki A; Yasui N; Ono S; Otani K; Kaneko S
    Psychiatry Res; 2001 Feb; 101(1):33-8. PubMed ID: 11223117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia.
    Bitsios P; Roussos P
    Pharmacogenomics; 2011 Apr; 12(4):559-66. PubMed ID: 21521027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia.
    Strous RD; Lapidus R; Viglin D; Kotler M; Lachman HM
    Neurosci Lett; 2006 Jan; 393(2-3):170-3. PubMed ID: 16233957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.